Fundraising FoxJeito Capital — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsBioGeneration VenturesBioMedPartnersForbionPictet GroupAsahi Kasei Corporate Venture CapitalSeroba Life Sciences
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)
Board seatKsenija Pavletic· per SEC Form D
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+9 more
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.